OBJECTIVE: To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children. METHODS: Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy. Liver biopsy was performed before and at the end of therapy. Four children had low and three had moderate viremia. RESULTS: At twelve weeks, two children (28.6%) lost viremia. Another child lost viremia at 52 weeks. ETR was 42.9%. During follow up one relapsed, thus SVR was 28.6%. Children with SVR were the youngest, their mean duration of infection was 4.5 vs 12.7 years in the others. Side effects of both INF & ribavirin was mild, required no reduction in doses. CONCLUSION: Combination therapy of peg interferon-alpha with ribavirin is well tolerated in children and adolescents studied.
OBJECTIVE: To evaluate safety and efficacy of Peg-INF combined with ribavirin for genotype 4 infected children. METHODS: Seven children were included, five were infected parentrally, One vertically and one had both exposures. Clinical and laboratory evaluation were undertaken as well as quantitative PCR for HCV RNA before therapy at, 12, 24 and 52 weeks during treatment and one year after therapy. Liver biopsy was performed before and at the end of therapy. Four children had low and three had moderate viremia. RESULTS: At twelve weeks, two children (28.6%) lost viremia. Another child lost viremia at 52 weeks. ETR was 42.9%. During follow up one relapsed, thus SVR was 28.6%. Children with SVR were the youngest, their mean duration of infection was 4.5 vs 12.7 years in the others. Side effects of both INF & ribavirin was mild, required no reduction in doses. CONCLUSION: Combination therapy of peg interferon-alpha with ribavirin is well tolerated in children and adolescents studied.
Authors: S M Kamal; A A El Tawil; T Nakano; Q He; J Rasenack; S A Hakam; W A Saleh; A Ismail; A A Aziz; M Ali Madwar Journal: Gut Date: 2005-06 Impact factor: 23.059
Authors: Mostafa K Mohamed; Laurence S Magder; Mohamed Abdel-Hamid; May El-Daly; Nabiel N Mikhail; Fatma Abdel-Aziz; Ahmed Medhat; Valerie Thiers; G Thomas Strickland Journal: Am J Trop Med Hyg Date: 2006-07 Impact factor: 2.345
Authors: M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis Journal: N Engl J Med Date: 1999-08-19 Impact factor: 91.245
Authors: Stefan Wirth; Heidrun Pieper-Boustani; Thomas Lang; Antje Ballauff; Ulrike Kullmer; Patrick Gerner; Philip Wintermeyer; Andreas Jenke Journal: Hepatology Date: 2005-05 Impact factor: 17.425
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: F Z Alfaleh; Q Hadad; M S Khuroo; A Aljumah; A Algamedi; H Alashgar; M N Al-Ahdal; I Mayet; M Q Khan; G Kessie Journal: Liver Int Date: 2004-12 Impact factor: 5.828
Authors: F Roudot-Thoraval; J M Pawlotsky; V Thiers; L Deforges; P P Girollet; F Guillot; C Huraux; P Aumont; C Brechot; D Dhumeaux Journal: Hepatology Date: 1993-05 Impact factor: 17.425
Authors: K Domagalski; M Pawłowska; A Tretyn; W Halota; M Pilarczyk; E Smukalska; K Linkowska; T Grzybowski Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-13 Impact factor: 3.267